These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 30461252)

  • 1. [Determination of receptor and HER2 status of breast cancer using tissue matrix technology. Validation of the method].
    Kudaibergenova AG; Turkevich EA; Artemieva AS
    Vopr Onkol; 2016; 62(2):314-9. PubMed ID: 30461252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
    Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
    J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma.
    Drev P; Grazio SF; Bracko M
    Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):179-84. PubMed ID: 18227723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-evaluation of HER2 status in 606 breast cancers-gene protein assay on tissue microarrays versus routine pathological assessment.
    Sandén E; Khazaei S; Tryggvadottir H; Borgquist S; Isaksson K; Jirström K; Jernström H
    Virchows Arch; 2020 Aug; 477(2):317-320. PubMed ID: 32080761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Image cytometric validation of breast carcinoma markers (ER, HER2 and MIB-1) using tissue microarrays: rabbit monoclonal vs. FDA-approved antibodies.
    Nassar A; Norton CM; Lawson D; Cohen C
    Anal Quant Cytol Histol; 2010 Aug; 32(4):192-200. PubMed ID: 21434519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer.
    Diaz LK; Gupta R; Kidwai N; Sneige N; Wiley EL
    J Histochem Cytochem; 2004 Apr; 52(4):501-7. PubMed ID: 15034001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
    Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A
    Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
    Graham AD; Faratian D; Rae F; Thomas JS
    Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High agreement between whole slide imaging and optical microscopy for assessment of HER2 expression in breast cancer: whole slide imaging for the assessment of HER2 expression.
    Nunes C; Rocha R; Buzelin M; Balabram D; Foureaux F; Porto S; Gobbi H
    Pathol Res Pract; 2014 Nov; 210(11):713-8. PubMed ID: 25091257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Andersen J; Overgaard J
    Acta Oncol; 2008; 47(4):591-9. PubMed ID: 18465327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of antigenicity in stored sections of breast cancer tissue microarrays.
    Fergenbaum JH; Garcia-Closas M; Hewitt SM; Lissowska J; Sakoda LC; Sherman ME
    Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):667-72. PubMed ID: 15066936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
    Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
    Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
    Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
    Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of a novel and low cost technique to construct paraffin tissue microarrays out of paraffinised needle biopsy specimens from patients with breast cancer.
    Vogel UF; Bültmann B
    J Clin Pathol; 2010 Jul; 63(7):640-3. PubMed ID: 20591915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
    Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
    Ricardo SA; Milanezi F; Carvalho ST; Leitão DR; Schmitt FC
    J Clin Pathol; 2007 Sep; 60(9):1001-5. PubMed ID: 17158643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer.
    Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
    Anticancer Res; 2016 Sep; 36(9):4661-6. PubMed ID: 27630309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
    Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
    J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer.
    Tramm T; Kyndi M; Sørensen FB; Overgaard J; Alsner J
    Acta Oncol; 2018 Jan; 57(1):102-106. PubMed ID: 29202620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.